ArticleClinical ophthalmology (Auckland, N.Z.)2026
Epidemiology and Associated Ocular Conditions of Visual Impairment in the United States: A Decade of Data from TriNetX US Network.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To characterize the demographic profile, within-cohort prevalence of associated ocular conditions, and trends in the incidence and prevalence of visual impairment in the United States using a large, real-world clinical database. Methods: We conducted a retrospective cohort study utilizing the TriNetX US Collaborative Network. Patients with visual impairment and associated ocular conditions potentially contributing to visual impairment were identified using ICD-10 codes between January 1, 2014 and January 1, 2026. Demographic characteristics, within-cohort prevalence of associated ocular conditions, and annual incidence and prevalence within the network were analyzed. Results: A total of 805,428 patients with visual impairment were identified. The mean current age was 55.3 ± 26.0 years, with slightly more females (52.93%). Most patients were White (61.68%), followed by Black or African American (20.92%) and Hispanic or Latino (11.54%). Cataract (18.5%), glaucoma (13.9%), age-related macular degeneration (9.7%), and diabetic retinopathy (6.6%) were the most frequently observed associated ocular conditions in our cohort. Between 2014 and 2025, the annual incidence of visual impairment increased significantly from 124.56 to 212.69 per 100,000 persons (P < 0.001). Prevalence increased from 471.56 to 1433.70 per 100,000 persons (P < 0.001). Conclusion: Visual impairment affected a broad demographic spectrum, with cataract, glaucoma, age-related macular degeneration, and diabetic retinopathy being the leading associated ocular conditions. Network-based incidence and prevalence increased over the decade, reflecting both true epidemiologic trends and network expansion. These findings highlight the importance of targeted screening, early detection, and timely treatment, particularly among high-risk and underserved populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.